Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 19, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Predicting responders to therapies for multiple sclerosis.

Jordi Río1, Manuel Comabella, Xavier Montalban

  • 1Multiple Sclerosis Centre of Catalonia, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-120, Barcelona, Spain.

Nature Reviews. Neurology
|October 2, 2009
PubMed
Summary

Monitoring treatment response in relapsing-remitting multiple sclerosis (RRMS) is crucial. This review examines clinical measures, MRI, and pharmacogenomics for predicting therapy effectiveness and guiding treatment decisions.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Related Experiment Videos

Last Updated: Jun 19, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Medical Imaging

Background:

  • Current therapies for relapsing-remitting multiple sclerosis (RRMS) show limited efficacy, with persistent disease activity in many patients.
  • Early identification of non-responders to disease-modifying agents is essential to prevent irreversible neurological damage.
  • Existing clinical criteria for treatment response lack independent validation and consensus.

Purpose of the Study:

  • To review and evaluate proposed approaches for monitoring and predicting treatment responses in patients with RRMS.
  • To assess the utility of clinical measures, MRI, and pharmacogenomics in managing RRMS therapy.

Main Methods:

  • Review of existing literature on clinical assessment criteria for RRMS treatment response.
  • Evaluation of Magnetic Resonance Imaging (MRI) as a tool for detecting subclinical disease activity.
  • Discussion of emerging pharmacogenomic approaches for personalized MS therapy.

Main Results:

  • Clinical measures based on relapses and disability progression are proposed but lack consensus and validation.
  • MRI offers valuable subclinical data on disease activity, complementing clinical monitoring.
  • Pharmacogenomics shows promise for tailoring RRMS treatments to individual patients.

Conclusions:

  • Accurate monitoring of treatment response in RRMS is vital for optimizing patient outcomes.
  • A combination of clinical evaluation, MRI, and potentially pharmacogenomics may improve treatment selection and monitoring.
  • Further research and validation are needed to establish definitive methods for predicting and monitoring treatment response in RRMS.